about
Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancerPreclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model systemMUC1 and MUC2 expression in pancreatic ductal carcinoma obtained by fine-needle aspiration.Ex vivo transfer of the Hoxc-8-interacting domain of Smad1 by a tropism-modified adenoviral vector results in efficient bone formation in a rabbit model of spinal fusion.A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancerConditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancerTherapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasisA phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.LL-37 as a therapeutic target for late stage prostate cancer.Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer.A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status.Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenovirusesA mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathwayDepletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells.Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma.Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational controlp53 Nuclear accumulation and Bcl-2 expression in contiguous adenomatous components of colorectal adenocarcinomas predict aggressive tumor behaviorExpression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model.A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancerPromotion of incisional wound repair by human mesenchymal stem cell transplantation.Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.alpha-CaMKII controls the growth of human osteosarcoma by regulating cell cycle progression.Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer.Location of tumor affects local and distant immune cell type and numberDetection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and correlation with prognosis.Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma.Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma.Clinicopathological factors associated with survival in patients with breast cancer brain metastasis.The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma.The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma.Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein.Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system.
P50
Q21132306-56A78B96-A20B-47FC-AD17-74FEE6C75047Q25257352-8022692D-31A6-4C62-94CC-FAF7365FD07CQ31033212-9EE09C3F-E022-4032-84C7-620914B499AFQ33642730-B546710E-E453-4B8C-B5CB-3FCD368742DAQ33786353-8875FE87-0B5A-42B9-949A-7558F7993A94Q34055529-F4C9A696-F753-40F6-8664-7A68154B46F5Q34147824-E95A2F88-118B-4423-AFB3-D97EC65914EDQ34268524-522A6A48-D6D5-4F99-BED6-141743D8C194Q34511108-FED0D89E-08BF-40DF-B098-8F9296B34151Q35071668-0D87B235-8784-483B-AEE6-CC63AEC329A7Q35101968-E33E9707-D3A8-4868-9E0C-1A21C45B6F10Q35189857-1542C839-C01D-4EE9-B74B-266CFB2F2950Q35754085-6FD2A5CB-C075-4F7E-A7FB-C9308F869202Q36387918-91D64214-EC85-4A73-8D4B-BF85BA3A079FQ36398900-142A03EE-0EC4-4FCF-AB44-5C282006E9ECQ36493469-7AC7B978-1343-44EE-B3E6-B0630F1175ABQ36496709-6CDD04DC-119E-4AE8-8D84-E123B55552A5Q36498617-333A6B8D-1328-4EFC-9727-779510BE13E5Q36572871-FFEA92A0-ED77-43FE-A4D6-B112094094E3Q36644377-4636DD27-6D6D-4211-B0A0-C0DF8B5BA34BQ37107332-C9E9C614-75CC-44B0-B7AD-B80AA41F7D28Q37147819-8BCFCC63-7B52-411C-B4E0-D7C63ECA80A8Q37277441-AE37DE6E-4EEB-44E3-BB69-5E4981955E43Q37319003-39348B82-FB19-428A-BB3D-2B08F6ABE662Q37371697-A3E29273-607C-47BA-B5B1-7FEA96DA7711Q37481753-3122B762-94D2-472B-BAB2-68A304917EFEQ37660747-4D83ADB9-3C3F-4744-8149-086660DF328FQ38388250-8C37D33C-7760-4CE6-B104-6F8637AABB47Q38507328-C42583B8-6636-4B92-8F29-B850CA708C8DQ39954445-24215492-8D63-44AF-9359-6F08B88BB7F0Q39995055-25194743-BD56-4211-B2A0-3A83475E6E5CQ40063020-445C1EF8-9839-4620-9C50-0C2DF75AC303Q40072806-88BBC9F7-2DE9-4A20-89B5-296D95B7C0B9Q40203638-F3B2CE72-6A1A-4BD1-96A9-FCD29191BFFBQ40224383-9DA352D4-7CE4-4D72-BBEC-CD7BFA74D6A3Q40233827-4D410884-9CBE-4D47-A670-8D7C970AEAF5Q40291112-E09FA09A-1631-4272-962A-BB7B2B37E0B1Q40342635-30051BAD-A3B6-4A39-83A9-55D237BFC832Q40349320-1E870C77-05EB-4A75-BF2E-44147446FAB3Q40370150-23A6E88C-8B2B-4C67-AD47-1EB9A98EE16D
P50
description
researcher (ORCID 0000-0003-3857-3368)
@en
wetenschapper
@nl
باحث (معرف أورسيد 0000-0003-3857-3368)
@ar
name
Gene P. Siegal
@en
Gene P. Siegal
@nl
type
label
Gene P. Siegal
@en
Gene P. Siegal
@nl
prefLabel
Gene P. Siegal
@en
Gene P. Siegal
@nl
P31
P496
0000-0003-3857-3368